Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Accounts Payables (2016 - 2025)

Anaptysbio's Accounts Payables history spans 10 years, with the latest figure at $3.9 million for Q4 2025.

  • For Q4 2025, Accounts Payables fell 3.27% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $3.9 million, down 3.27%, while the annual FY2025 figure was $3.9 million, 3.27% down from the prior year.
  • Accounts Payables reached $3.9 million in Q4 2025 per ANAB's latest filing, up from $2.9 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $6.5 million in Q3 2023 to a low of $1.6 million in Q2 2022.
  • Average Accounts Payables over 5 years is $3.8 million, with a median of $3.7 million recorded in 2024.
  • Peak YoY movement for Accounts Payables: crashed 71.39% in 2021, then soared 200.0% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $1.7 million in 2021, then surged by 59.91% to $2.8 million in 2022, then soared by 68.75% to $4.7 million in 2023, then fell by 14.81% to $4.0 million in 2024, then fell by 3.27% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Accounts Payables are $3.9 million (Q4 2025), $2.9 million (Q3 2025), and $3.3 million (Q2 2025).